Sun Pharma Advanced Research Company Limited — Others, 18-07-2025: Shareholders meeting

SPARC's board approved its annual financial results for FY25, showing a consolidated loss of ₹342.51 Cr against ₹71.77 Cr in revenue; no dividend was proposed due to the losses. Operationally, the company received USFDA clearance for its SBO-154 IND application and advanced SCD-153 into Phase 1b clinical trials. SPARC has called its 20th Annual General Meeting to consider adopting these financials, re-appointing a director, and seeking shareholder approval for key related party transactions, including boosting a credit line to ₹550 Cr, and enabling future fundraising up to ₹1,800 Cr.